Rothschild Investment Corp IL acquired a new position in shares of Ardelyx, Inc. (NASDAQ:ARDX) in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 46,700 shares of the biopharmaceutical company’s stock, valued at approximately $309,000.
Other institutional investors and hedge funds have also recently bought and sold shares of the company. Pacer Advisors Inc. grew its holdings in Ardelyx by 66.9% in the first quarter. Pacer Advisors Inc. now owns 3,896 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 1,562 shares during the period. DekaBank Deutsche Girozentrale acquired a new stake in Ardelyx in the fourth quarter worth $196,000. Los Angeles Capital Management LLC grew its holdings in Ardelyx by 8.6% in the fourth quarter. Los Angeles Capital Management LLC now owns 45,404 shares of the biopharmaceutical company’s stock worth $294,000 after purchasing an additional 3,610 shares during the period. Dimensional Fund Advisors LP grew its holdings in Ardelyx by 0.4% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,860,556 shares of the biopharmaceutical company’s stock worth $12,039,000 after purchasing an additional 7,511 shares during the period. Finally, UBS Asset Management Americas Inc. grew its holdings in Ardelyx by 21.3% in the fourth quarter. UBS Asset Management Americas Inc. now owns 61,000 shares of the biopharmaceutical company’s stock worth $395,000 after purchasing an additional 10,700 shares during the period. Institutional investors own 85.92% of the company’s stock.
In other Ardelyx news, insider David P. Rosenbaum sold 5,000 shares of Ardelyx stock in a transaction dated Tuesday, April 6th. The shares were sold at an average price of $8.00, for a total value of $40,000.00. Following the sale, the insider now owns 160,047 shares of the company’s stock, valued at $1,280,376. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 3.96% of the company’s stock.
Ardelyx (NASDAQ:ARDX) last announced its quarterly earnings data on Sunday, March 7th. The biopharmaceutical company reported ($0.32) EPS for the quarter, missing the consensus estimate of ($0.26) by ($0.06). The company had revenue of $1.81 million during the quarter, compared to the consensus estimate of $1.87 million. Ardelyx had a negative return on equity of 53.93% and a negative net margin of 1,063.74%. Analysts forecast that Ardelyx, Inc. will post -1 earnings per share for the current year.
A number of equities research analysts have commented on ARDX shares. Zacks Investment Research upgraded shares of Ardelyx from a “sell” rating to a “hold” rating in a report on Wednesday, March 10th. Wedbush initiated coverage on shares of Ardelyx in a report on Monday, March 29th. They set an “outperform” rating and a $14.00 price objective for the company. Finally, Cantor Fitzgerald initiated coverage on shares of Ardelyx in a report on Tuesday, January 5th. They set an “overweight” rating and a $14.00 price objective for the company. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Ardelyx presently has an average rating of “Buy” and an average price target of $12.44.
Ardelyx, Inc, a biopharmaceutical company, develops and sells medicines for the treatment of cardiorenal diseases in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase 3 clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase 3 clinical trial for the treatment of hyperphosphatemia in end-stage renal disease patients on dialysis.
Further Reading: Trading Halts
Receive News & Ratings for Ardelyx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ardelyx and related companies with MarketBeat.com's FREE daily email newsletter.